22 May 2013
Keywords: pfizer/avant, candidate, may, increase, survival, rate, gbm
Article | 16 June 2008
USA-based Avant and global drug giant Pfizer released new data from two Phase II studies for CDX-110, an investigational immunotherapeutic
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 June 2008
21 May 2013
© 2013 thepharmaletter.com